Article
Oncology
Song Y. Park, Austin R. Green, Rouba Hadi, Coley Doolittle-Amieva, Jennifer Gardner, Ata S. Moshiri
Summary: Talimogene laherparepvec (T-VEC) is a popular treatment option for surgically non-resectable, recurrent melanoma. Clinical observations show rapid tumor size decrease and prolonged improvement in pigmentation, possibly due to tumorous melanosis. Biopsies after clinical responses reveal non-viable or absent tumor tissue with tumorous melanosis.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Pier Francesco Ferrucci, Laura Pala, Fabio Conforti, Emilia Cocorocchio
Summary: Talimogene laherparepvec (T-VEC) is an oncolytic viral immunotherapy approved for the treatment of melanoma, aiming to trigger immune responses locally and potentially synergize with immune checkpoint inhibitors.
Article
Dermatology
E. H. A. Stahlie, A. C. J. van Akkooi, E. Plasmeijer
Summary: This study investigated the feasibility of dermoscopy in monitoring the response to T-VEC. The results showed that dermoscopy can provide additional information for cutaneous melanoma metastases (CMM) with a pink pattern, but not for those with other patterns.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Oncology
Evalyn E. A. P. Mulder, Emma H. A. Stahlie, Danielle Verver, Clara Lemstra, Lukas B. Been, Antien L. Mooyaart, Tessa Brabander, Erik Vegt, Frederik A. Verburg, Astrid A. M. van der Veldt, Cornelis Verhoef, Alexander C. J. van Akkooi, Dirk J. Grunhagen
Summary: T-VEC treatment may lead to new FDG uptake in locoregional lymph nodes, which could be falsely classified as suspected metastases. Physicians should be cautious of the high false positive rate of FDG uptake during T-VEC treatment and consider pathological examination of lymph node lesions to differentiate between disease progression and immune infiltration.
JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Evalyn E. A. P. Mulder, Jeffrey Damman, Danielle Verver, Astrid A. M. van der Veldt, Sam Tas, Tamana Khemai-Mehraban, Kim C. Heezen, Roxane A. Wouters, Cornelis Verhoef, Georges M. G. M. Verjans, Anton W. Langerak, Dirk J. Grunhagen, Antien L. Mooyaart
Summary: T-VEC treatment in melanoma patients leads to the presence of plasma cells in biopsy samples. An angiocentric granulomatous pattern is associated with a durable complete response. These findings suggest that plasma cells may play a role in the response mechanism.
Article
Oncology
Jason A. Chesney, Antoni Ribas, Georgina Long, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew Haydon, John Hyngstrom, Johannes van Thienen, Sebastian Haferkamp, Josep Malvehy Guilera, Bernardo Leon Rapoport, Ari VanderWalde, Scott J. Diede, James R. Anderson, Sheryl Treichel, Edward L. Chan, Sumita Bhatta, Jennifer Gansert, Frank Stephen Hodi, Helen Gogas
Summary: In this phase III study, the combination of T-VEC and pembrolizumab did not significantly improve progression-free survival or overall survival in patients with advanced melanoma. These findings indicate that this combination therapy is not effective in this patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Julia Maria Ressler, Matthias Karasek, Lukas Koch, Rita Silmbrod, Joanna Mangana, Sofiya Latifyan, Veronica Aedo-Lopez, Helmut Kehrer, Felix Weihsengruber, Peter Koelblinger, Christian Posch, Julian Kofler, Olivier Michielin, Erika Richtig, Christine Hafner, Christoph Hoeller
Summary: The study assessed the outcomes of 88 melanoma patients treated with T-VEC, showing an overall response rate of 63.7% and 43.2% achieving a complete response. The median treatment period was 19 weeks, with 45.3% of patients experiencing adverse events, mostly mild in nature.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Dermatology
Ania Henning, Doreen Agnese, Catherine G. Chung
Summary: Talimogene laherparepvec (TVEC) is a genetically modified herpes simplex virus-1 used for the treatment of advanced melanoma. However, cutaneous reactions at the injection site may mimic recurrent melanoma. We reported a case of pseudolymphomatous reaction after TVEC therapy in a patient with metastatic melanoma.
JOURNAL OF CUTANEOUS PATHOLOGY
(2021)
Review
Oncology
Emma H. A. Stahlie, Evalyn E. A. P. Mulder, Sophie Reijers, Sara Balduzzi, Charlotte L. Zuur, Willem M. C. Klop, Bernies van der Hiel, Bart A. Van de Wiel, Michel W. J. M. Wouters, Yvonne M. Schrage, Winan J. van Houdt, Dirk J. Grunhagen, Alexander C. J. van Akkooi
Summary: Single-agent T-VEC is effective and well-tolerated in the treatment of unresectable and injectable stage III-IV melanoma, achieving high response rates especially in early metastatic melanoma patients.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Oncology
Viola Franke, Emma H. A. Stahlie, Willem M. C. Klop, Charlotte L. L. Zuur, Danique M. S. Berger, Bernies van der Hiel, Bart A. A. van de Wiel, Michel W. J. M. Wouters, Winan J. J. van Houdt, Alexander C. J. van Akkooi
Summary: Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus used for intralesional treatment in patients with unresectable melanoma in the head and neck region. It has shown promising results and can be considered as an alternative to systemic therapy in this patient population.
Article
Biochemistry & Molecular Biology
R. Dummer, D. E. Gyorki, J. Hyngstrom, A. C. Berger, R. Conry, L. Demidov, A. Sharma, S. A. Treichel, H. Radcliffe, K. S. Gorski, A. Anderson, E. Chan, M. Faries, M. I. Ross
Summary: The study found that intralesional injection of an oncolytic virus prior to surgery is clinically beneficial for patients with locally advanced, resectable melanoma, leading to improved recurrence-free survival.
Letter
Oncology
Reinhard Dummer, David E. Gyorki, John R. Hyngstrom, Meng Ning, Tatiana Lawrence, Merrick I. Ross
Summary: This article presents the final 5-year follow-up results of neoadjuvant T-VEC plus surgery in patients with advanced melanoma.
Article
Oncology
Michael J. Carr, James Sun, Danielle DePalo, Luke D. Rothermel, Yun Song, Richard J. Straker, Kristin Baecher, Raphael J. Louie, Emma H. A. Stahlie, G. Paul Wright, Syeda Mahrukh Hussnain Naqvi, Youngchul Kim, Amod A. Sarnaik, Giorgos C. Karakousis, Michael C. Lowe, Keith A. Delman, Alexander C. J. van Akkooi, David W. Ollila, Frances Collichio, Jonathan S. Zager
Summary: This study demonstrates the efficacy of T-VEC in patients with unresectable, metastatic stage IIIB-IV melanoma after failure of IO. The timing of T-VEC initiation, sequentially or concurrently after IO, did not significantly impact in-field response.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Howard L. Kaufman, Sophia Z. Shalhout, Gail Iodice
Summary: This review provides an overview of the advancements in using T-VEC for melanoma patients and its expansion to non-melanoma cancers. The clinical trial results of T-VEC combination studies are also discussed, along with strategies to identify predictive biomarkers. The review sets the stage for future investigations and highlights the potential of oncolytic viruses in treating cancer.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Article
Health Care Sciences & Services
Olaf M. Neve, Peter Paul G. van Benthem, Anne M. Stiggelbout, Erik F. Hensen
Summary: This study assessed the impact of different delivery methods on patient response rates for PRO surveys. Surveys delivered by regular mail had the highest response rate, followed by hybrid and email delivery methods. Lower response rates were associated with lower education levels and longer time intervals since the last outpatient clinic visit.
BMC MEDICAL RESEARCH METHODOLOGY
(2021)
Article
Oncology
Antoni Ribas, Adil Daud, Anna C. Pavlick, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Matthew Wongchenko, Isabelle Rooney, Jessie J. Hsu, Yibing Yan, Erica Park, Grant A. McArthur
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Omid Hamid, Rubina Ismail, Igor Puzanov
Article
Oncology
Janice M. Mehnert, Emily Bergsland, Bert H. O'Neil, Armando Santoro, Jan H. M. Schellens, Roger B. Cohen, Toshihiko Doi, Patrick A. Ott, Michael J. Pishvaian, Igor Puzanov, Kyaw L. Aung, Chiun Hsu, Christophe Le Tourneau, Antoine Hollebecque, Elena Elez, Kenji Tamura, Marlena Gould, Ping Yang, Karen Stein, Sarina A. Piha-Paul
Editorial Material
Medicine, Research & Experimental
Franco Maria Buonaguro, Igor Puzanov, Paolo Antonio Ascierto
JOURNAL OF TRANSLATIONAL MEDICINE
(2020)
Article
Medicine, Research & Experimental
Paolo A. Ascierto, Sanjiv S. Agarwala, Alexander Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Olivier Michielin, Michael Postow, Igor Puzanov, Hassane M. Zarour, Corrado Caraco, Alessandro Testori
JOURNAL OF TRANSLATIONAL MEDICINE
(2020)
Review
Oncology
Rohit Gosain, Yara Abdou, Abhay Singh, Navpreet Rana, Igor Puzanov, Marc S. Ernstoff
CURRENT ONCOLOGY REPORTS
(2020)
Article
Multidisciplinary Sciences
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood, Sebastiano Battaglia, Saby George, Gurkamal Chatta, Igor Puzanov, Carl Morrison, Kunle Odunsi, Brahm H. Segal, Grace K. Dy, Marc S. Ernstoff, Fumito Ito
Summary: Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but durable response is limited. CX3CR1, a marker of T-cell differentiation, is investigated as a predictor of response to ICI therapy. Treatment with ICI increases the frequency of circulating CX3CR1(+)CD8(+) T cells and correlates with response and survival in patients with non-small cell lung cancer.
NATURE COMMUNICATIONS
(2021)
Review
Oncology
Benjamin Switzer, Igor Puzanov, Joseph J. Skitzki, Lamya Hamad, Marc S. Ernstoff
Summary: This review summarizes the historical and future advances regarding the translational and clinical implications of advanced melanoma and provides multidisciplinary recommendations to aid clinicians in the navigation of current treatment approaches for a variety of patient cohorts.
JCO ONCOLOGY PRACTICE
(2022)
Article
Oncology
Jason A. Chesney, Antoni Ribas, Georgina Long, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew Haydon, John Hyngstrom, Johannes van Thienen, Sebastian Haferkamp, Josep Malvehy Guilera, Bernardo Leon Rapoport, Ari VanderWalde, Scott J. Diede, James R. Anderson, Sheryl Treichel, Edward L. Chan, Sumita Bhatta, Jennifer Gansert, Frank Stephen Hodi, Helen Gogas
Summary: In this phase III study, the combination of T-VEC and pembrolizumab did not significantly improve progression-free survival or overall survival in patients with advanced melanoma. These findings indicate that this combination therapy is not effective in this patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jason A. Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed M. Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodore Logan, Axel Hauschild, Celeste Lebbe, Harshada Joshi, Wendy Snyder, Janice M. Mehnert
Summary: In a randomized phase II study, the combination of T-VEC and ipilimumab showed greater antitumor activity compared to ipilimumab alone in patients with advanced melanoma. The 5-year outcomes demonstrated long-lasting efficacy and safety for the combination therapy of an oncolytic virus and a checkpoint inhibitor.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Islam Eljilany, Payman Ghasemi Saghand, James Chen, Aakrosh Ratan, Martin McCarter, John Carpten, Howard Colman, Alexandra P. Ikeguchi, Igor Puzanov, Susanne Arnold, Michelle Churchman, Patrick Hwu, Jose Conejo-Garcia, William S. Dalton, George J. Weiner, Issam M. El Naqa, Ahmad A. Tarhini
Summary: In this study, the prognostic value of immunoscore calculated from real-world transcriptomic data was evaluated in patients with advanced malignancies treated with immune checkpoint inhibitors. The results demonstrated that the immunoscore could predict patients at risk of death, with better overall survival observed in patients with intermediate-high immunoscore.
Article
Oncology
Lei Deng, Changchuan Jiang, Kristopher Attwood, Joseph J. Zhao, Stuthi Perimbeti, Chen Hu, Igor Puzanov, Grace K. Dy
Summary: Durable progression-free survivors (dPFSors) over 2 years have been reported among patients with melanoma or non-small-cell lung cancer (NSCLC) who received PD-(L)1 therapy. However, risk of progression still exists and the optimal imaging surveillance interval is unknown.
JCO ONCOLOGY PRACTICE
(2023)
Meeting Abstract
Oncology
Latha Shivakumar, Christine B. Weldon, Ali McBride, Igor Puzanov, Joanne Riemer, Matthew R. Zibelman, Leigh Boehmer
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Meeting Abstract
Medicine, Research & Experimental
Adi Diab, Igor Puzanov, Michele Maio, Brendan Curti, Mehmet Bilen, Karl Lewis, Scott Tykodi, Gregory Daniels, Alexander Spira, Chantale Bernatchez, Salah Eddine Bentebibel, Michael Wong, James Larkin, Ewa Kalinka-Warzocha, Sunny Xie, Sue Currie, Ute Hoch, Wei Lin, Mary Tagliaferri, Stina Singel, Michael Hurwitz
JOURNAL OF TRANSLATIONAL MEDICINE
(2020)
Review
Oncology
Nikhil Agrawal, Arjun Khunger, Pankit Vachhani, Teresa A. Colvin, Alexander Hattoum, Edward Spangenthal, Anne B. Curtis, Grace K. Dy, Marc S. Ernstoff, Igor Puzanov
CASE REPORTS IN ONCOLOGY
(2019)